PanZhengMDPhD

Pathology • Rockville, MD

Anatomic Pathology, Clinical Pathology

Physician

Join to view full profile

Dr. Zheng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zheng's full profile

Already have an account?

Office
9430 Key West Ave
Ste 113
Rockville, MD 20850

Education & Training

NYU Grossman School of MedicineResidency, Pathology-Anatomic and Clinical, 1994 - 1998
Peking Union Medical CollegeClass of 1987

Certifications & Licensure

MD State Medical License 2014 - 2025
DC State Medical License 2015 - 2022
MI State Medical License 2006 - 2022
VA State Medical License 2014 - 2020
OH State Medical License 1998 - 2007
NY State Medical License 1997 - 1999
American Board of Pathology Clinical Pathology

Clinical Trials

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Start of enrollment: 2020 Sep 16
Recruiting
Phase 1, Phase 2

Publications & Presentations

PubMed

148 citations
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction
Guo-Yun Chen, Xi Chen, Samantha J. King, Karen A. Cavassani, Jiansong Cheng
Nature Biotechnology. 2011-05-01
49 citations
Siglecg Limits the Size of B1a B Cell Lineage by Down-Regulating NFκB Activation
Cheng Ding, Yan Liu, Yin Wang, Bae Keun Park, Cun-Yu Wang
Plos One. 2007-10-03
590 citations
CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses
Guo-Yun Chen, Jie Tang, Pan Zheng, Yang Liu
Science. 2009-03-27

Journal Articles

CD24 and Fc Fusion Protein Protects SIVmac239-Infected Chinese Rhesus Macaque Against Progression to AIDS
Pan Zheng, MD, ScienceDirect

Press Mentions

UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022
OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with Pembrolizumab at SITC 2022November 7th, 2022
Join now to see all